RU2001910C1 - Способ получени хинолинового производного - Google Patents
Способ получени хинолинового производногоInfo
- Publication number
- RU2001910C1 RU2001910C1 SU904831426A SU4831426A RU2001910C1 RU 2001910 C1 RU2001910 C1 RU 2001910C1 SU 904831426 A SU904831426 A SU 904831426A SU 4831426 A SU4831426 A SU 4831426A RU 2001910 C1 RU2001910 C1 RU 2001910C1
- Authority
- RU
- Russia
- Prior art keywords
- dihydro
- oxo
- calculated
- elemental analysis
- chlorophenyl
- Prior art date
Links
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title abstract 2
- 238000000034 method Methods 0.000 title description 23
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract description 28
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract description 12
- 125000003545 alkoxy group Chemical group 0.000 abstract description 10
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract description 9
- 239000000460 chlorine Substances 0.000 abstract description 9
- 229910052801 chlorine Inorganic materials 0.000 abstract description 9
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 abstract description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 6
- 238000006243 chemical reaction Methods 0.000 abstract description 5
- 229910052731 fluorine Inorganic materials 0.000 abstract description 5
- 239000011737 fluorine Substances 0.000 abstract description 5
- 125000001153 fluoro group Chemical group F* 0.000 abstract description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract description 3
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 abstract description 2
- 108010054082 Sterol O-acyltransferase Proteins 0.000 abstract description 2
- 150000004703 alkoxides Chemical class 0.000 abstract description 2
- 239000003153 chemical reaction reagent Substances 0.000 abstract 2
- 229940123324 Acyltransferase inhibitor Drugs 0.000 abstract 1
- 239000002404 acyltransferase inhibitor Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 115
- 238000000921 elemental analysis Methods 0.000 description 77
- 239000000203 mixture Substances 0.000 description 55
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- 150000001875 compounds Chemical class 0.000 description 33
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- 239000013078 crystal Substances 0.000 description 25
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 21
- -1 4- {2-chlorophenyl) -1,2-dihydro-1,6,8-trimethyl-2-oxo-3 quinolyl Chemical group 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 238000001953 recrystallisation Methods 0.000 description 17
- 238000003756 stirring Methods 0.000 description 17
- UXTMROKLAAOEQO-UHFFFAOYSA-N chloroform;ethanol Chemical compound CCO.ClC(Cl)Cl UXTMROKLAAOEQO-UHFFFAOYSA-N 0.000 description 14
- 238000001816 cooling Methods 0.000 description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
- 235000012000 cholesterol Nutrition 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 201000001320 Atherosclerosis Diseases 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000004202 carbamide Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- GCFHZZWXZLABBL-UHFFFAOYSA-N ethanol;hexane Chemical compound CCO.CCCCCC GCFHZZWXZLABBL-UHFFFAOYSA-N 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 150000001840 cholesterol esters Chemical class 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 3
- IEEHKTFVUIVORU-UHFFFAOYSA-N 2-methylpropanedioyl dichloride Chemical compound ClC(=O)C(C)C(Cl)=O IEEHKTFVUIVORU-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- BOQDZPHCWCIRRY-UHFFFAOYSA-N ethyl 4-(3,4-dimethoxyphenyl)-6-methyl-2-oxo-1h-quinoline-3-carboxylate Chemical compound C12=CC(C)=CC=C2NC(=O)C(C(=O)OCC)=C1C1=CC=C(OC)C(OC)=C1 BOQDZPHCWCIRRY-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 2
- NMJWILRMCPEMLK-UHFFFAOYSA-N 3-amino-4-(2-chlorophenyl)-1,6,7-trimethylquinolin-2-one Chemical compound NC=1C(=O)N(C)C=2C=C(C)C(C)=CC=2C=1C1=CC=CC=C1Cl NMJWILRMCPEMLK-UHFFFAOYSA-N 0.000 description 2
- WVCHIKCSPJPRLX-UHFFFAOYSA-N 4-(2-chlorophenyl)-1,6,7-trimethyl-2-oxoquinoline-3-carboxylic acid Chemical compound OC(=O)C=1C(=O)N(C)C=2C=C(C)C(C)=CC=2C=1C1=CC=CC=C1Cl WVCHIKCSPJPRLX-UHFFFAOYSA-N 0.000 description 2
- YYSNEOZYIJSAOB-UHFFFAOYSA-N 6-chloro-4-phenylquinolin-3-amine Chemical compound NC1=CN=C2C=CC(Cl)=CC2=C1C1=CC=CC=C1 YYSNEOZYIJSAOB-UHFFFAOYSA-N 0.000 description 2
- 102000057234 Acyl transferases Human genes 0.000 description 2
- 108700016155 Acyl transferases Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- TXHIDIHEXDFONW-UHFFFAOYSA-N benzene;propan-2-one Chemical compound CC(C)=O.C1=CC=CC=C1 TXHIDIHEXDFONW-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- OYJXTOVLKZDGFK-UHFFFAOYSA-N ethanol;2-propan-2-yloxypropane Chemical compound CCO.CC(C)OC(C)C OYJXTOVLKZDGFK-UHFFFAOYSA-N 0.000 description 2
- XOUJUXDQMMPVRM-UHFFFAOYSA-N ethyl 4-(2-chlorophenyl)-6,8-dimethyl-2-oxo-1h-quinoline-3-carboxylate Chemical compound C12=CC(C)=CC(C)=C2NC(=O)C(C(=O)OCC)=C1C1=CC=CC=C1Cl XOUJUXDQMMPVRM-UHFFFAOYSA-N 0.000 description 2
- OORDCPZWRJNLRZ-UHFFFAOYSA-N ethyl 4-(2-chlorophenyl)-6-ethyl-1-methyl-2-oxoquinoline-3-carboxylate Chemical compound C12=CC(CC)=CC=C2N(C)C(=O)C(C(=O)OCC)=C1C1=CC=CC=C1Cl OORDCPZWRJNLRZ-UHFFFAOYSA-N 0.000 description 2
- VLIZXFDJQKSJEL-UHFFFAOYSA-N ethyl 6-chloro-1-methyl-4-(2-methylphenyl)-2-oxoquinoline-3-carboxylate Chemical compound C12=CC(Cl)=CC=C2N(C)C(=O)C(C(=O)OCC)=C1C1=CC=CC=C1C VLIZXFDJQKSJEL-UHFFFAOYSA-N 0.000 description 2
- SVCHBFMHCNGGLT-UHFFFAOYSA-N ethyl 6-chloro-4-(2-chlorophenyl)-1-methyl-2-oxoquinoline-3-carboxylate Chemical compound C12=CC(Cl)=CC=C2N(C)C(=O)C(C(=O)OCC)=C1C1=CC=CC=C1Cl SVCHBFMHCNGGLT-UHFFFAOYSA-N 0.000 description 2
- SWYGIPJLKMEMBI-UHFFFAOYSA-N ethyl 6-chloro-4-(2-chlorophenyl)-2-oxo-1h-quinoline-3-carboxylate Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)OCC)=C1C1=CC=CC=C1Cl SWYGIPJLKMEMBI-UHFFFAOYSA-N 0.000 description 2
- YJZVOKFQCWKJEH-UHFFFAOYSA-N ethyl 6-chloro-4-(2-methylphenyl)-2-oxo-1h-quinoline-3-carboxylate Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)OCC)=C1C1=CC=CC=C1C YJZVOKFQCWKJEH-UHFFFAOYSA-N 0.000 description 2
- ICMCMGITQHAYGT-UHFFFAOYSA-N ethyl 7-chloro-6-methyl-4-(2-methylphenyl)-2-oxo-1h-quinoline-3-carboxylate Chemical compound C12=CC(C)=C(Cl)C=C2NC(=O)C(C(=O)OCC)=C1C1=CC=CC=C1C ICMCMGITQHAYGT-UHFFFAOYSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- SDLYGCDHGGJYAL-UHFFFAOYSA-N methyl 4-(2-chlorophenyl)-1,6,7-trimethyl-2-oxoquinoline-3-carboxylate Chemical compound C12=CC(C)=C(C)C=C2N(C)C(=O)C(C(=O)OC)=C1C1=CC=CC=C1Cl SDLYGCDHGGJYAL-UHFFFAOYSA-N 0.000 description 2
- WSYHBYIEEVPZKH-UHFFFAOYSA-N methyl 4-(2-chlorophenyl)-1,6,8-trimethyl-2-oxoquinoline-3-carboxylate Chemical compound C12=CC(C)=CC(C)=C2N(C)C(=O)C(C(=O)OC)=C1C1=CC=CC=C1Cl WSYHBYIEEVPZKH-UHFFFAOYSA-N 0.000 description 2
- IRZIHUCGSLAMDQ-UHFFFAOYSA-N methyl 4-(2-chlorophenyl)-1-ethyl-6,7-dimethyl-2-oxoquinoline-3-carboxylate Chemical compound COC(=O)C=1C(=O)N(CC)C2=CC(C)=C(C)C=C2C=1C1=CC=CC=C1Cl IRZIHUCGSLAMDQ-UHFFFAOYSA-N 0.000 description 2
- ZZVHVJNMLYBXFP-UHFFFAOYSA-N methyl 4-(2-chlorophenyl)-2,6,8-trimethylquinoline-3-carboxylate Chemical compound COC(=O)C1=C(C)N=C2C(C)=CC(C)=CC2=C1C1=CC=CC=C1Cl ZZVHVJNMLYBXFP-UHFFFAOYSA-N 0.000 description 2
- YIXLLADLYBVCLE-UHFFFAOYSA-N methyl 6,7-dimethyl-4-(2-methylphenyl)-2-oxo-1h-quinoline-3-carboxylate Chemical compound C12=CC(C)=C(C)C=C2NC(=O)C(C(=O)OC)=C1C1=CC=CC=C1C YIXLLADLYBVCLE-UHFFFAOYSA-N 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- DDSPDJNVPFJTEJ-UHFFFAOYSA-N (2-amino-3,4-dimethoxyphenyl)-phenylmethanone Chemical compound NC1=C(OC)C(OC)=CC=C1C(=O)C1=CC=CC=C1 DDSPDJNVPFJTEJ-UHFFFAOYSA-N 0.000 description 1
- ZUWXHHBROGLWNH-UHFFFAOYSA-N (2-amino-5-chlorophenyl)-phenylmethanone Chemical compound NC1=CC=C(Cl)C=C1C(=O)C1=CC=CC=C1 ZUWXHHBROGLWNH-UHFFFAOYSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- CNSMSQGVOSMXNU-UHFFFAOYSA-N (4-isocyanato-2,6-dimethoxyphenyl) acetate Chemical compound COC1=CC(N=C=O)=CC(OC)=C1OC(C)=O CNSMSQGVOSMXNU-UHFFFAOYSA-N 0.000 description 1
- IFRGISXBQCGGSZ-UHFFFAOYSA-N (6-amino-3,6-dichlorocyclohexa-2,4-dien-1-yl)-phenylmethanone Chemical compound NC1(Cl)C=CC(Cl)=CC1C(=O)C1=CC=CC=C1 IFRGISXBQCGGSZ-UHFFFAOYSA-N 0.000 description 1
- WKWQMVTWNAEOMA-UHFFFAOYSA-N (6-amino-6-chloro-3,5-dimethylcyclohexa-2,4-dien-1-yl)-phenylmethanone Chemical compound NC1(C(C(=O)C2=CC=CC=C2)C=C(C=C1C)C)Cl WKWQMVTWNAEOMA-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ZKOVTKFEQCBWJT-UHFFFAOYSA-N 1-benzyl-3-(6,7-dimethoxy-4-phenylquinolin-3-yl)urea Chemical compound C=1C=CC=CC=1C1=C2C=C(OC)C(OC)=CC2=NC=C1NC(=O)NCC1=CC=CC=C1 ZKOVTKFEQCBWJT-UHFFFAOYSA-N 0.000 description 1
- CEPCPXLLFXPZGW-UHFFFAOYSA-N 2,4-difluoroaniline Chemical compound NC1=CC=C(F)C=C1F CEPCPXLLFXPZGW-UHFFFAOYSA-N 0.000 description 1
- LUYXVKNRFKSASY-UHFFFAOYSA-N 2-oxo-4-phenyl-1h-quinoline-3-carboxylic acid Chemical compound C12=CC=CC=C2NC(=O)C(C(=O)O)=C1C1=CC=CC=C1 LUYXVKNRFKSASY-UHFFFAOYSA-N 0.000 description 1
- YRPINTOLVWDIMX-UHFFFAOYSA-N 4-(2-chlorophenyl)-1,6,8-trimethyl-2-oxoquinoline-3-carboxylic acid Chemical compound C12=CC(C)=CC(C)=C2N(C)C(=O)C(C(O)=O)=C1C1=CC=CC=C1Cl YRPINTOLVWDIMX-UHFFFAOYSA-N 0.000 description 1
- DLKUCJSRJQSEOV-UHFFFAOYSA-N 4-(2-chlorophenyl)-1-ethyl-6,7-dimethyl-2-oxoquinoline-3-carboxylic acid Chemical compound OC(=O)C=1C(=O)N(CC)C2=CC(C)=C(C)C=C2C=1C1=CC=CC=C1Cl DLKUCJSRJQSEOV-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- ORYYQSTYNMOPOF-UHFFFAOYSA-N 6,7-dimethoxy-4-phenylquinolin-3-amine Chemical compound NC=1C=NC2=CC(=C(C=C2C1C1=CC=CC=C1)OC)OC ORYYQSTYNMOPOF-UHFFFAOYSA-N 0.000 description 1
- LTMSPQNIXZITLT-UHFFFAOYSA-N 6-chloro-1-methyl-4-(2-methylphenyl)-2-oxoquinoline-3-carboxylic acid Chemical compound CC1=CC=CC=C1C1=C(C(O)=O)C(=O)N(C)C2=CC=C(Cl)C=C12 LTMSPQNIXZITLT-UHFFFAOYSA-N 0.000 description 1
- HAMHNJRELYSNHU-UHFFFAOYSA-N 6-chloro-4-(2-chlorophenyl)-1-methyl-2-oxoquinoline-3-carboxylic acid Chemical compound OC(=O)C=1C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1Cl HAMHNJRELYSNHU-UHFFFAOYSA-N 0.000 description 1
- BBIUBHTUENDRIM-UHFFFAOYSA-N 6-chloro-4-(2-chlorophenyl)-2-methoxyquinoline-3-carboxylic acid Chemical compound OC(=O)C=1C(OC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1Cl BBIUBHTUENDRIM-UHFFFAOYSA-N 0.000 description 1
- ZJYAOSBDALNGSC-UHFFFAOYSA-N 6-chloro-4-(3,4-dimethoxyphenyl)-1-methyl-2-oxoquinoline-3-carboxylic acid Chemical compound C1=C(OC)C(OC)=CC=C1C1=C(C(O)=O)C(=O)N(C)C2=CC=C(Cl)C=C12 ZJYAOSBDALNGSC-UHFFFAOYSA-N 0.000 description 1
- YUMIMBSPDCGBKP-UHFFFAOYSA-N 7-chloro-1,6-dimethyl-4-(2-methylphenyl)-2-oxoquinoline-3-carboxylic acid Chemical compound CC1=CC=CC=C1C1=C(C(O)=O)C(=O)N(C)C2=CC(Cl)=C(C)C=C12 YUMIMBSPDCGBKP-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- IYXGSMUGOJNHAZ-UHFFFAOYSA-N Ethyl malonate Chemical group CCOC(=O)CC(=O)OCC IYXGSMUGOJNHAZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WRQNANDWMGAFTP-UHFFFAOYSA-N Methylacetoacetic acid Chemical compound COC(=O)CC(C)=O WRQNANDWMGAFTP-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- LUBJCRLGQSPQNN-UHFFFAOYSA-N Z-phenylurea Natural products NC(=O)NC1=CC=CC=C1 LUBJCRLGQSPQNN-UHFFFAOYSA-N 0.000 description 1
- GPWHDDKQSYOYBF-UHFFFAOYSA-N ac1l2u0q Chemical compound Br[Br-]Br GPWHDDKQSYOYBF-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 108700014220 acyltransferase activity proteins Proteins 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- ISULCYCJYHCOTR-UHFFFAOYSA-N ethyl 2,6-dichloro-4-(2-chlorophenyl)quinoline-3-carboxylate Chemical compound CCOC(=O)C1=C(Cl)N=C2C=CC(Cl)=CC2=C1C1=CC=CC=C1Cl ISULCYCJYHCOTR-UHFFFAOYSA-N 0.000 description 1
- KPRKRRJKKCVDDE-UHFFFAOYSA-N ethyl 4-(2-chlorophenyl)-1-methyl-2-oxo-6-propan-2-ylquinoline-3-carboxylate Chemical compound C12=CC(C(C)C)=CC=C2N(C)C(=O)C(C(=O)OCC)=C1C1=CC=CC=C1Cl KPRKRRJKKCVDDE-UHFFFAOYSA-N 0.000 description 1
- GLUQXXOXABKJAJ-UHFFFAOYSA-N ethyl 4-(2-chlorophenyl)-2-methoxy-6,8-dimethylquinoline-3-carboxylate Chemical compound CCOC(=O)C1=C(OC)N=C2C(C)=CC(C)=CC2=C1C1=CC=CC=C1Cl GLUQXXOXABKJAJ-UHFFFAOYSA-N 0.000 description 1
- ROGVDGJPKUHARL-UHFFFAOYSA-N ethyl 4-(2-chlorophenyl)-2-oxo-6-propan-2-yl-1h-quinoline-3-carboxylate Chemical compound C12=CC(C(C)C)=CC=C2NC(=O)C(C(=O)OCC)=C1C1=CC=CC=C1Cl ROGVDGJPKUHARL-UHFFFAOYSA-N 0.000 description 1
- KQLTUTYMWRVEGZ-UHFFFAOYSA-N ethyl 4-(2-chlorophenyl)-6-ethyl-2-oxo-1h-quinoline-3-carboxylate Chemical compound C12=CC(CC)=CC=C2NC(=O)C(C(=O)OCC)=C1C1=CC=CC=C1Cl KQLTUTYMWRVEGZ-UHFFFAOYSA-N 0.000 description 1
- YLTPUGQKOOWPIB-UHFFFAOYSA-N ethyl 6-chloro-1-methyl-2-oxo-4-phenylquinoline-3-carboxylate Chemical compound C12=CC(Cl)=CC=C2N(C)C(=O)C(C(=O)OCC)=C1C1=CC=CC=C1 YLTPUGQKOOWPIB-UHFFFAOYSA-N 0.000 description 1
- YNNAVLGZRMNKDA-UHFFFAOYSA-N ethyl 6-chloro-2-oxo-4-phenyl-1h-quinoline-3-carboxylate Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)OCC)=C1C1=CC=CC=C1 YNNAVLGZRMNKDA-UHFFFAOYSA-N 0.000 description 1
- KGMXVSCDDAPHFJ-UHFFFAOYSA-N ethyl 6-chloro-4-(3,4-dimethoxyphenyl)-1-methyl-2-oxoquinoline-3-carboxylate Chemical compound C12=CC(Cl)=CC=C2N(C)C(=O)C(C(=O)OCC)=C1C1=CC=C(OC)C(OC)=C1 KGMXVSCDDAPHFJ-UHFFFAOYSA-N 0.000 description 1
- MZWJHZLLXJPENY-UHFFFAOYSA-N ethyl 6-chloro-4-(3,4-dimethoxyphenyl)-2-oxo-1h-quinoline-3-carboxylate Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)OCC)=C1C1=CC=C(OC)C(OC)=C1 MZWJHZLLXJPENY-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- MOTRZVVGCFFABN-UHFFFAOYSA-N hexane;2-propan-2-yloxypropane Chemical compound CCCCCC.CC(C)OC(C)C MOTRZVVGCFFABN-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- MNETVZHOUVQZPV-UHFFFAOYSA-N methyl 2-oxo-4-phenyl-1h-quinoline-3-carboxylate Chemical compound C12=CC=CC=C2NC(=O)C(C(=O)OC)=C1C1=CC=CC=C1 MNETVZHOUVQZPV-UHFFFAOYSA-N 0.000 description 1
- ODFDDSSSXDWTDP-UHFFFAOYSA-N methyl 4-(2-chlorophenyl)-6,7-dimethyl-2-oxo-1h-quinoline-3-carboxylate Chemical compound C12=CC(C)=C(C)C=C2NC(=O)C(C(=O)OC)=C1C1=CC=CC=C1Cl ODFDDSSSXDWTDP-UHFFFAOYSA-N 0.000 description 1
- YHQBBABNRWKMFT-UHFFFAOYSA-N methyl 6-chloro-4-(2-chlorophenyl)-2-methoxyquinoline-3-carboxylate Chemical compound COC(=O)C1=C(OC)N=C2C=CC(Cl)=CC2=C1C1=CC=CC=C1Cl YHQBBABNRWKMFT-UHFFFAOYSA-N 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- XDUHQPOXLUAVEE-BPMMELMSSA-N oleoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCC\C=C/CCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 XDUHQPOXLUAVEE-BPMMELMSSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- CPGRMGOILBSUQC-UHFFFAOYSA-N phosphoryl azide Chemical compound [N-]=[N+]=NP(=O)(N=[N+]=[N-])N=[N+]=[N-] CPGRMGOILBSUQC-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- AAZYNPCMLRQUHI-UHFFFAOYSA-N propan-2-one;2-propan-2-yloxypropane Chemical compound CC(C)=O.CC(C)OC(C)C AAZYNPCMLRQUHI-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- LOAUVZALPPNFOQ-UHFFFAOYSA-N quinaldic acid Chemical compound C1=CC=CC2=NC(C(=O)O)=CC=C21 LOAUVZALPPNFOQ-UHFFFAOYSA-N 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- VEJHIZHVFWVWRQ-UHFFFAOYSA-N syringic acid acetate Chemical compound COC1=CC(C(O)=O)=CC(OC)=C1OC(C)=O VEJHIZHVFWVWRQ-UHFFFAOYSA-N 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Measurement Of Radiation (AREA)
- Holo Graphy (AREA)
- Detergent Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP26278289 | 1989-10-06 | ||
| JP32229089 | 1989-12-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2001910C1 true RU2001910C1 (ru) | 1993-10-30 |
Family
ID=26545706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU904831426A RU2001910C1 (ru) | 1989-10-06 | 1990-10-05 | Способ получени хинолинового производного |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5223513A (enExample) |
| EP (1) | EP0421456B1 (enExample) |
| KR (1) | KR910007883A (enExample) |
| CN (1) | CN1050715A (enExample) |
| AT (1) | ATE116301T1 (enExample) |
| AU (1) | AU629048B2 (enExample) |
| CA (1) | CA2026890C (enExample) |
| DE (1) | DE69015541T2 (enExample) |
| FI (1) | FI904915A7 (enExample) |
| HU (1) | HUT55364A (enExample) |
| IE (1) | IE903454A1 (enExample) |
| IL (1) | IL95839A (enExample) |
| NO (1) | NO904300L (enExample) |
| NZ (1) | NZ235582A (enExample) |
| PT (1) | PT95515A (enExample) |
| RU (1) | RU2001910C1 (enExample) |
| TW (1) | TW205037B (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2240998C2 (ru) * | 1998-12-04 | 2004-11-27 | Бристол-Маерс Сквибб Компани | Производные 3-замещенного 4-арилхинолин-2-она в качестве модуляторов калиевых каналов |
| RU2259355C2 (ru) * | 2001-04-30 | 2005-08-27 | Пфайзер Продактс Инк. | Способ получения ингибитора сетр, промежуточное вещество и способ его получения |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03181465A (ja) * | 1989-12-11 | 1991-08-07 | Takeda Chem Ind Ltd | キノリン誘導体 |
| AU1879792A (en) * | 1991-04-26 | 1992-12-21 | Pfizer Inc. | 4-aryl-3-(heteroarylureido)quinoline derivatives |
| ATE175196T1 (de) * | 1992-01-23 | 1999-01-15 | Pfizer | 4-phenyl-3-(heteroarylureido)-1,2-dihydro-2- oxochinolin derivate, als antihypercholesterolemische und antiatherosklerotische mittel |
| TW241258B (enExample) * | 1992-04-15 | 1995-02-21 | Takeda Pharm Industry Co Ltd | |
| RU94046149A (ru) * | 1992-05-28 | 1996-11-27 | Пфайзер Инк. (US) | Новые n-арил и n-гетероарил производные мочевины как ингибиторы ацил кофермента а:холестерин ацил трансферазы (асат) фармацевтическая композиция, способ ингибирования (асат) |
| DE69315920T2 (de) * | 1992-09-04 | 1998-06-10 | Takeda Chemical Industries Ltd | Kondensierte heterozyklische Verbindungen, deren Herstellung und Verwendung |
| US5565472A (en) * | 1992-12-21 | 1996-10-15 | Pfizer Inc. | 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-oxo-quinoline derivatives as antihypercholesterolemic and antiatherosclerotic agents |
| NZ264063A (en) * | 1993-08-13 | 1995-11-27 | Nihon Nohyaku Co Ltd | N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions |
| TW263498B (enExample) * | 1993-11-10 | 1995-11-21 | Takeda Pharm Industry Co Ltd | |
| US6133326A (en) | 1994-08-31 | 2000-10-17 | Pfizer Inc | Compositions and methods for decreasing sebum production |
| US5843957A (en) * | 1995-05-19 | 1998-12-01 | Sumitomo Pharmaceuticals Company, Ltd. | Naphthyridine derivatives |
| JP2001513560A (ja) * | 1997-08-28 | 2001-09-04 | ブリストル−マイヤーズ スクイブ カンパニー | ４−アリール−３−アミノキノリン−２−オン誘導体カリウムチャンネル調節剤 |
| US6452008B2 (en) | 1998-02-25 | 2002-09-17 | Sumitomo Pharmaceuticals Company, Limited | Pyridone derivatives and process for preparing the same |
| WO1999043659A1 (en) | 1998-02-25 | 1999-09-02 | Sumitomo Pharmaceuticals Co., Ltd. | Pyridone derivatives and process for producing the same |
| HUP0301010A3 (en) * | 2000-02-02 | 2005-03-29 | Warner Lambert Co | Dual inhibitors of cholesteryl ester and wax ester synthesis for sebaceous gland disorders and pharmaceutical compositions containing them |
| EP1375487B1 (en) * | 2001-03-02 | 2011-08-24 | Sumitomo Chemical Company, Limited | Process for producing quinoline-3-carboxylic acid compounds |
| CA2539760C (en) | 2003-09-23 | 2011-01-25 | Merck & Co., Inc. | Quinoline potassium channel inhibitors |
| SG11201401937YA (en) * | 2011-11-04 | 2014-05-29 | Hoffmann La Roche | New aryl-quinoline derivatives |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1216878B (de) * | 1963-04-02 | 1966-05-18 | Cassella Farbwerke Mainkur Ag | Verfahren zur Herstellung von coronargefaesserweiternden Derivaten des 7-Hydroxy-2-oxo-1, 2-dihydrochinolins |
| NO133758C (enExample) * | 1970-04-04 | 1976-06-23 | Takeda Chemical Industries Ltd | |
| JPS555502B1 (enExample) * | 1971-07-31 | 1980-02-07 | ||
| US4530931A (en) * | 1983-01-03 | 1985-07-23 | Usv Pharmaceutical Corp. | 8-Quinoline carbanilates for the inhibition of lipolysis |
| DE3586445T2 (de) * | 1984-06-26 | 1993-01-14 | Merck & Co Inc | Kondensierte benzo-laktam-verbindungen und deren pharmazeutische zusammensetzungen. |
| IE892088L (en) * | 1988-07-12 | 1990-01-12 | William Henry Deryk Morris | Quinoline derivatives, their production and use |
-
1990
- 1990-09-20 TW TW079107912A patent/TW205037B/zh active
- 1990-09-25 IE IE345490A patent/IE903454A1/en unknown
- 1990-09-25 US US07/587,795 patent/US5223513A/en not_active Expired - Fee Related
- 1990-09-28 AU AU63707/90A patent/AU629048B2/en not_active Ceased
- 1990-09-28 IL IL9583990A patent/IL95839A/en not_active IP Right Cessation
- 1990-10-03 NO NO90904300A patent/NO904300L/no unknown
- 1990-10-04 PT PT95515A patent/PT95515A/pt not_active Application Discontinuation
- 1990-10-04 CA CA002026890A patent/CA2026890C/en not_active Expired - Fee Related
- 1990-10-05 HU HU906360A patent/HUT55364A/hu unknown
- 1990-10-05 FI FI904915A patent/FI904915A7/fi not_active Application Discontinuation
- 1990-10-05 NZ NZ235582A patent/NZ235582A/en unknown
- 1990-10-05 RU SU904831426A patent/RU2001910C1/ru active
- 1990-10-05 DE DE69015541T patent/DE69015541T2/de not_active Expired - Fee Related
- 1990-10-05 AT AT90119128T patent/ATE116301T1/de not_active IP Right Cessation
- 1990-10-05 CN CN90108222A patent/CN1050715A/zh active Pending
- 1990-10-05 EP EP90119128A patent/EP0421456B1/en not_active Expired - Lifetime
- 1990-10-06 KR KR1019900015908A patent/KR910007883A/ko not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2240998C2 (ru) * | 1998-12-04 | 2004-11-27 | Бристол-Маерс Сквибб Компани | Производные 3-замещенного 4-арилхинолин-2-она в качестве модуляторов калиевых каналов |
| RU2259355C2 (ru) * | 2001-04-30 | 2005-08-27 | Пфайзер Продактс Инк. | Способ получения ингибитора сетр, промежуточное вещество и способ его получения |
Also Published As
| Publication number | Publication date |
|---|---|
| IL95839A (en) | 1995-03-15 |
| CN1050715A (zh) | 1991-04-17 |
| DE69015541D1 (de) | 1995-02-09 |
| HUT55364A (en) | 1991-05-28 |
| ATE116301T1 (de) | 1995-01-15 |
| HU906360D0 (en) | 1991-04-29 |
| DE69015541T2 (de) | 1995-06-01 |
| CA2026890C (en) | 2001-09-18 |
| AU629048B2 (en) | 1992-09-24 |
| NO904300D0 (no) | 1990-10-03 |
| EP0421456B1 (en) | 1994-12-28 |
| CA2026890A1 (en) | 1991-04-07 |
| FI904915A7 (fi) | 1991-04-07 |
| NO904300L (no) | 1991-04-08 |
| IL95839A0 (en) | 1991-06-30 |
| US5223513A (en) | 1993-06-29 |
| EP0421456A3 (en) | 1991-05-29 |
| TW205037B (enExample) | 1993-05-01 |
| JPH03223254A (ja) | 1991-10-02 |
| NZ235582A (en) | 1992-03-26 |
| KR910007883A (ko) | 1991-05-30 |
| PT95515A (pt) | 1991-08-14 |
| IE903454A1 (en) | 1991-04-10 |
| FI904915A0 (fi) | 1990-10-05 |
| AU6370790A (en) | 1991-04-11 |
| EP0421456A2 (en) | 1991-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4668686A (en) | Imidazoquinoline antithrombrogenic cardiotonic agents | |
| US3702849A (en) | 4-(isoquinolin-1-yl) piperazine-1-carboxylic acid esters | |
| EP0268989B1 (en) | Imidazopyridine compounds and processes for preparation thereof | |
| US4656174A (en) | Quinoline therapeutic agents | |
| EP0354994B1 (en) | Quinoline derivatives, their production and use | |
| CA2026890C (en) | Quinoline derivatives, their production and use | |
| US3847921A (en) | Pharmacologically active 3-piperazinyl-carbonyloxy-2-pyridyl-isoindolin-1-ones | |
| US4782055A (en) | Imidazopyridine compounds useful in the treatment of ulcers | |
| US5679677A (en) | Heterocyclic carbamates, process for their preparation and medicaments | |
| EP0399422A1 (en) | Benzocycloalkane derivatives and production thereof | |
| JPH0550512B2 (enExample) | ||
| EP0228959B1 (en) | Aminostyryl compound, leukotriene antagonistic composition containing the same as effective ingredients and method of antagonizing srs by employing the same | |
| JP4231107B2 (ja) | 抗ウイルス作用を有する置換キノリン誘導体 | |
| US4243666A (en) | 4-Amino-2-piperidino-quinazolines | |
| EP0138491A2 (en) | Substituted 2(1H)-quinazolinone-1-alkanoic acids and esters | |
| JPH0859621A (ja) | 置換キノリン誘導体、それらの製造方法およびそれらの使用 | |
| JPH0673012A (ja) | ４−イミノキノリン、その製法およびその使用 | |
| EP0472116A1 (en) | Thienopyridine Derivatives, their production and use | |
| JPH0764816B2 (ja) | 複素環化合物 | |
| NZ562541A (en) | Dihydropyridine derivatives | |
| JP2003511381A (ja) | 新規なイミダゾピリジンカルボニトリル化合物 | |
| EP0243982B1 (en) | 1-acyl-2,3-dihydro-4(1h)-quinolinone-4-oxime derivative, process for the production thereof, pharmaceutical composition and intermediates | |
| JPS61218571A (ja) | 新規ラクタム誘導体及び新規チオラクタム誘導体並びに抗炎症剤 | |
| US3647802A (en) | 2-amino-4-aryl-3 4-dihydroquinolines | |
| CA1322752C (en) | Heteroarylcarboxamide derivatives, process for preparing the same and pharmaceutical composition containing the same |